[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ZIWIG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100636066","impact-of-endotest-on-patients-quality-of-life-a-cohort-study-100636066",false,"NCT07560852","Impact of Endotest on Patients' Quality of Life: a Cohort Study","ENDOLIFE","Inclusion Criteria:\n\n* Women with a prescription for Endotest\n* Women aged 18 to 43\n* Who have dated and signed the consent form\n* Affiliated with the French healthcare system or covered by health insurance abroad\n\nExclusion Criteria:\n\n* Contraindications for the use of Endotest:\n\n  1. Current pregnancy;\n  2. Medical history of cancer or HIV infection;\n  3. Active infection at the time of saliva collection;\n* Significant difficulty reading and understanding the language of the country in which the participant is located.","FEMALE","18 Years","43 Years",{"count":20,"type":21},20000,"ESTIMATED","16 Months","OBSERVATIONAL","Ziwig Endotest® ('Endotest') is marketed in several countries, including Switzerland, which was the first country to make it available in 2022. Since February 2025, several French clinical investigation sites have been offering Endotest, developed by Ziwig, under the innovation funding. Initially, this innovation funding enabled 2,500 patients to be included in a clinical trial (ENDOBEST: ID-RCB 2024-A02092-45). Since the end of December 2025, it has been expanded and now covers a further 22,500 patients whose are not included in the trial. This medical device is based on Next-Generation Sequencing combined with analytical algorithms and enables the identification of endometriosis from a saliva sample. This non-invasive test aims to improve patient care by reducing diagnostic delays and guiding treatment strategies.\n\nDespite the available data on its diagnostic performance, the impact of Endotest on patients' quality of life, their emotional experience, their coping strategies, and their care pathways remains insufficiently documented. Indeed, the Endotest result (positive or negative) can significantly influence these various aspects. This cohort study aims to assess the impact of Endotest on patients' quality of life, primarily using validated self-report questionnaires and clinical data from medical records. By including a large sample of patients, this study aims to provide robust and generalisable data that will be useful for clinicians and patients themselves.",[26,27],"Patient With a Prescribed Endotest","Endometriosis (Diagnosis)",[29],"endometriosis","RECRUITING","2026-05-20",{"date":33,"type":34},"2026-05-26","ACTUAL",{"date":36,"type":34},"2026-05-06",{"date":38,"type":21},"2029-07-31",{"name":40,"class":41},"ZIWIG","INDUSTRY",7,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100546289","evaluation-of-salivary-rna-in-subjects-scheduled-for-surgery-for-a-gynecologic-pathology-100546289","NCT06392997","Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology","GynRNA","Inclusion Criteria:\n\n1. Subject of legal age (according to local legislation) and at least 18 years old\n2. Subject (and if applicable her legal representative) having dated and signed the informed consent form\n3. Subject with a medical insurance policy\n4. Subject presenting to the department:\n\n   1. With Symptoms (bleeding and\u002For pain and\u002For clinically observed symptom) of one or more of the following pathologies (suspected undergoing diagnostic surgery\u002Fbiopsy or diagnosed and before any curative treatment of the pathology):\n\n      * Endometriosis\n      * Adenomyosis,\n      * Ovarian cysts,\n      * Fibroids,\n      * Ovarian cancer,\n      * Cervical cancer,\n      * Uterine cancer.\n   2. Asymptomatic with pap smear positive for cervical dysplasia or cervical cancer and before any curative treatment.\n   3. Asymptomatic undergoing a pap smear for cervical cancer screening in a gynecological follow-up context.\n\nExclusion Criteria:\n\n1. Recent (\\\u003C1 month) or ongoing bacterial or viral infection\n2. Known active oral or digestive mycosis\n3. Evolving oral pathology, symptomatic or obvious\n4. Known pregnancy\n5. Known current non-gynecological pelvic pathology\n6. Subject with a diagnosed breast cancer or cancer other than gynecological with the exception of basal cell carcinoma\n7. Subject with a history of treated cancer within the last 5 years with the exception of basal cell carcinoma\n8. Subject who has already received chemotherapy or radiotherapy or undergone complete or partial excision of the gynecological pathology of inclusion criterion\n9. Subject with significant difficulties reading or writing her language\n10. Subject unable to comply with study and\u002For follow-up procedures\n11. Participation in an interventional study with investigational drug or in the exclusion period of an interventional study.",true,{"count":52,"type":21},2500,"GynRAN is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics\u002Fgynecological oncology departments that aims to identify a diagnostic signature for gynecological pathologies by analyzing of coding and non-coding RNA contained in patients saliva.\n\nThe study population consists of patients with clinically symptomatic females with one or more of the gynecological pathologies (endometriosis, adenomyosis, ovarian cysts, fibroids, ovarian\u002Fcervical\u002Futerine cancer) and asymptomatic females.\n\nThe patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations necessary according to the context, which are carried out according to the local recommendations.",[55,56,57,58,59,60,61,62],"Gynecologic Disease","Gynecologic Cancer","Endometriosis","Ovarian Cancer","Cyst Ovary","Fibroid","Cervical Cancer","Uterine Cancer","2025-01-20",{"date":65,"type":34},"2025-01-23",{"date":67,"type":34},"2024-12-05",{"date":69,"type":21},"2026-12",{"name":40,"class":41},13,""]